TESARO, Inc. (TSRO) Shares Bought by BlackRock Inc.
BlackRock Inc. grew its position in shares of TESARO, Inc. (NASDAQ:TSRO) by 5.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 3,605,247 shares of the biopharmaceutical company’s stock after purchasing an additional 195,590 shares during the period. BlackRock Inc. owned about 6.69% of TESARO worth $504,230,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. Botty Investors LLC bought a new stake in TESARO during the second quarter worth about $140,000. Meeder Asset Management Inc. bought a new stake in TESARO during the first quarter worth about $177,000. Oppenheimer Asset Management Inc. lifted its stake in TESARO by 3,042.6% during the second quarter. Oppenheimer Asset Management Inc. now owns 1,477 shares of the biopharmaceutical company’s stock worth $206,000 after purchasing an additional 1,430 shares during the last quarter. BB&T Securities LLC bought a new stake in TESARO during the second quarter worth about $222,000. Finally, Fox Run Management L.L.C. bought a new stake in TESARO during the second quarter worth about $224,000.
TESARO, Inc. (TSRO) opened at 119.04 on Monday. TESARO, Inc. has a one year low of $96.52 and a one year high of $192.94. The company’s 50-day moving average price is $121.03 and its 200-day moving average price is $138.94. The stock’s market cap is $6.45 billion.
TESARO (NASDAQ:TSRO) last announced its quarterly earnings data on Tuesday, August 8th. The biopharmaceutical company reported ($2.82) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.52) by ($0.30). The firm had revenue of $29.50 million during the quarter, compared to the consensus estimate of $18.61 million. TESARO had a negative return on equity of 104.00% and a negative net margin of 1,301.19%. The firm’s revenue for the quarter was down 17.6% on a year-over-year basis. During the same period in the previous year, the business earned ($1.28) EPS. Analysts forecast that TESARO, Inc. will post ($8.61) EPS for the current fiscal year.
Several brokerages have issued reports on TSRO. Cann reissued a “buy” rating and issued a $199.00 target price on shares of TESARO in a research note on Monday, June 5th. Citigroup Inc. reissued a “buy” rating and issued a $216.00 target price on shares of TESARO in a research note on Monday, September 11th. Robert W. Baird reissued a “neutral” rating and issued a $140.00 target price (down previously from $155.00) on shares of TESARO in a research note on Thursday, August 10th. Cowen and Company lowered their target price on TESARO from $145.00 to $124.00 and set a “market perform” rating for the company in a research note on Monday, June 19th. Finally, Credit Suisse Group set a $190.00 target price on TESARO and gave the company a “buy” rating in a research note on Friday, August 18th. One investment analyst has rated the stock with a sell rating, eleven have assigned a hold rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of “Buy” and a consensus target price of $171.42.
In other news, VP Grant C. Bogle sold 14,167 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The shares were sold at an average price of $135.00, for a total transaction of $1,912,545.00. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James O. Armitage sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $117.13, for a total transaction of $1,171,300.00. Following the transaction, the director now directly owns 10,000 shares in the company, valued at $1,171,300. The disclosure for this sale can be found here. In the last three months, insiders sold 35,100 shares of company stock valued at $4,558,765. 34.60% of the stock is owned by insiders.
TESARO Company Profile
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.
Want to see what other hedge funds are holding TSRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for TESARO, Inc. (NASDAQ:TSRO).
Receive News & Stock Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related stocks with our FREE daily email newsletter.